Begoña Pérez‐Valderrama

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer

Elena Castro, Nuria Romero-Laorden, Ángela del Pozo et al. · Journal of Clinical Oncology · 2019 · 372 citations · Full text

Medicine, Oncology, Urology +16

Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial

Jesús García-Donás, Albert Font, Begoña Pérez‐Valderrama et al. · The Lancet Oncology · 2017 · 50 citations

Medicine, Oncology, Pharmacotherapy +13

A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO).

Thomas Powles, James Larkin, Poulam M. Patel et al. · Journal of Clinical Oncology · 2019 · 50 citations

Medicine, Oncology, Pharmacology +14

Wnt/β-Catenin Signaling Contributes to Paclitaxel Resistance in Bladder Cancer Cells with Cancer Stem Cell-Like Properties

Rocío Jiménez‐Guerrero, Alejandro Belmonte‐Fernández, M. Luz Flores et al. · International Journal of Molecular Sciences · 2021 · 38 citations · Full text

Medicine, Cancer Biology, Oncology +17